Welcome to our dedicated page for KATN news (Ticker: KATN), a resource for investors and traders seeking the latest updates and insights on KATN stock.
The KATN news page on Stock Titan aggregates coverage related to Kineta, Inc., which is identified in TuHURA Biosciences, Inc.’s corporate communications as the target in a proposed merger transaction. In that disclosure, TuHURA describes a definitive agreement under which it would acquire Kineta, Inc. (OTC Pink: KATN) for a mix of cash and TuHURA common stock, with closing targeted for the second quarter of 2025 subject to funding and other conditions.
News linked to the KATN symbol is therefore closely tied to developments around this planned merger and the oncology asset it involves. TuHURA highlights that acquiring Kineta would include the rights to a novel VISTA inhibiting antibody, KVA12123, characterized as Phase 2 ready. TuHURA further notes its intention, after the anticipated closing of the merger, to move this VISTA inhibitor into a Phase 2 trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory acute myeloid leukemia (AML).
Readers following KATN-related news can expect items that reference the status of the proposed merger, regulatory and shareholder steps connected to the transaction, and TuHURA’s plans for the VISTA inhibiting antibody program once the acquisition is completed. Because the primary public context for KATN comes from TuHURA’s merger update, news flow is likely to emphasize corporate transaction milestones and the integration of Kineta’s oncology asset into TuHURA’s broader immuno-oncology pipeline as described in those communications.
Investors and observers can use this page to monitor how references to Kineta, Inc. (KATN), the proposed acquisition structure, and the VISTA inhibitor KVA12123 evolve in official announcements and related coverage over time.
TuHURA Biosciences (NASDAQ:HURA) reported its fiscal year 2024 results and corporate updates. The company plans to initiate enrollment in Phase 3 IFx-2.0 trial for advanced Merkel cell carcinoma in Q2 2025, conducted under Special Protocol Assessment Agreement with FDA. The trial will test IFx-2.0 as adjunctive therapy with Keytruda®.
Key financial highlights include R&D expenses of $13.3 million (up from $9.4 million in 2023) and G&A expenses of $4.3 million (slight increase from $4.1 million in 2023). The company raised $36 million in 2024 to fund operations through late Q4 2025.
Notable developments include:
- Planned acquisition of Kineta's Phase 2 ready VISTA inhibitor, expected to close in Q2 2025
- NASDAQ listing achievement via reverse merger
- Expansion of discovery team for immune modulating Antibody Drug/Peptide Conjugate Program